FDA
-
-
-
-
-
-
-
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
-
-
-
-
-
-
-
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
-
-
-
-
-
-
-
Ascentage Pharma to Participate in Evercore China Biotech Summit
-
-
-
-
-
-
-
Ascentage Pharma gets China approval for cancer drug lisaftoclax
-
-
-
-
-
-
-
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
-
-
-
-
-
322,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

